On May 5, 2025, Mersana Therapeutics announced a strategic restructuring plan to reduce its workforce by approximately 55%, with expected costs of $4-5 million due to severance and related expenses. The restructuring aims to focus on breast cancer development and is expected to be largely completed by the end of Q3 2025.